BEIGF:OTCMKTS
베이진
US$21.95
0.00%
(0.00) 1D
6월 9일, 오후 12시 49분 46초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoBEIGF의 주요 통계 생성 중...
시가총액
455.37억
평균 거래량
0.00
거래량
0.00
52주 최고가
US$24.92
52주 최저가
US$21.95
베타
0.86
유통 주식수
14.27억
직원 수
1만
시가총액
455.37억
평균 거래량
0.00
거래량
0.00
52주 최고가
US$24.92
52주 최저가
US$21.95
베타
0.86
유통 주식수
14.27억
직원 수
1만
뉴스 기사
웹 소스 및 뉴스 파트너 제공
Investor's Business Daily
·
1일 전
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
프로필
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
베이진에 관한 정보